Recent Updates
Recently added Catalysts
BON Positive Sentiment

BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products

Key Takeaway: Bon Natural Life Limited has announced a non-exclusive cooperation agreement worth $18 million with Beijing Huahai Keyuan Technology to distribute its innovative second-generation Apple Series health products in Greater China. This new product line boasts 80% higher bioactivity and aims to meet the growing demand in weight management and metabolic health. The company is optimistic about its market performance and potential revenue growth.
Price reaction · baseline $3.005 (2025-09-09T13:29:00.000Z) · hit during market hours · clean, no other BON news in the window
day 0 close
-36.1%
day 1
-35.8%
day 3 · peak
-36.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • BON has secured an $18 million cooperation agreement.
  • The second-generation Apple Series shows 80% higher bioactivity.
  • Market validation indicates strong consumer interest in nutraceutical products.
  • The company is well-positioned to lead in the metabolic health segment.

Full Press Release Details

XI'AN, China,Sept. 9, 2025/PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced it has entered into a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co. Ltd. ("Huahai Keyuan") a prominent health products distributor inChina. The term of the agreement is 24 months with a total contract value of US$18 million. Pursuant to the agreement, Huahai Keyuan will sell and distribute BON's innovative second-generation Apple Series health products acrossGreater China, tapping into significant market potential in the weight management and metabolic health sectors.
Leveraging advanced low-temperature extraction technology, BON's second-generation Apple Series delivers 80% higher bioactivity than its predecessor by improving the efficiency of the active ingredient extraction. This technological allows for a proprietary formulation that combines highly active apple polyphenols with plant protein, demonstrating strong efficacy in weight management and metabolic health applications.
After decades of evolution, protein supplements have become mainstream health essentials, integral to fitness regimens, immune support programs, and longevity-focused nutrition plans. BON's innovative incorporation of apple polyphenols into protein supplements delivers clinically validated benefits, including improved lipid metabolism, enhanced body composition, and reduced of age-related muscle loss - positioning the product at the intersection of established market needs and innovative functionality with significant growth potential.
Early market validation is encouraging, with comparable apple polyphenol blends generating over$40 millionin monthly sales. Industry analysts attribute this to consumers' growing willingness to pay for scientifically validated "nutraceutical products." BON management expressed confidence in achieving strong market performance given the competitive advantages of its second-generation formulation.
"We have both the responsibility and capability as a global leader in apple polyphenols to develop superior health solutions," stated Mr.Yongwei Hu, Chairman and CEO of BON. "Through our vertically integrated supply chain  - from raw materials to production - we are well-positioned to lead the rapidly growing metabolic health segment. The enhanced bioactivity of our second-generation apple polyphenols is expected to drive significant revenue and profit growth across nutraceutical and functional food markets, enhancing shareholder value and delivering strong returns."

About Bon Natural Life Limited ("BON")

BON is aCayman Islandscompany engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website athttp://www.bnlus.com.
For more information, please contact:Cindy Liu| IREmail:[email protected]

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Frequently Asked Questions

What is the value of BON's new cooperation agreement?

BON's cooperation agreement with Huahai Keyuan is valued at $18 million.

What are the key benefits of BON's second-generation Apple Series?

The second-generation Apple Series offers 80% higher bioactivity and supports weight management.

Who will distribute BON's Apple Series products?

Beijing Huahai Keyuan Technology will distribute BON's Apple Series health products.

What market does BON aim to tap with its new products?

BON aims to tap into the weight management and metabolic health markets.

Last updated: Sep 9, 2025